新型治疗药物用于心脏代谢风险减轻心脏移植接受者的心脏
Ananya Gorrai1, Maryjane Farr1, Patrick O'hara1
1Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas.
概括
针对高脂血症,糖尿病和肥胖症的新疗法对心脏移植接受者来说是有前途的. 这些药物可以减轻心脏代谢风险,调节免疫路径,尽管需要更多的研究.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏移植 (HT) 接受者容易患心脏代谢性疾病.
- 新型疗法如PCSK9抑制剂,SGLT2抑制剂和GLP-1激动剂在一般人群中常见于心脏代谢风险.
- 关于这些新药在HT后环境中的有效性和安全性的数据有限.
研究的目的:
- 审查新药药理学剂的作用机制.
- 探索新出现的证据,以证明它们在心脏移植接受者中用于减轻心脏代谢风险.
- 检查它们对调节免疫路径的潜力,这与移植后心血管并发症有关.
主要方法:
- 关于新药药理学药物的文献综述.
- 对作用机制的分析.
- 在心脏移植的背景下综合新兴证据.
- 对与心血管健康相关的免疫调节效应的审查.
主要成果:
- 针对高脂血症,糖尿病和肥胖症的新型药物已经在一般人群中发挥了作用.
- 新出现的证据表明,心脏移植接受者对心脏代谢风险降低有潜在的益处.
- 这些药物可能会影响免疫路径,这些路径涉及到动脉动脉生成,心上脂肪组织和冠状动脉移植血管病变.
结论:
- 新型药理学药剂是治疗心脏移植患者心脏代谢疾病的潜在策略.
- 需要进一步的临床研究来确定这种特定患者群体的安全性和有效性概况.
- 了解免疫调节效应可能为预防移植并发症提供新的途径.
更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
01:26Heart Failure Drugs: Inotropic Agents
516
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516